Please use this identifier to cite or link to this item:
Type
ArticleCopyright
Open access
Collections
- CDTS - Artigos de Periódicos [480]
- INI - Artigos de Periódicos [3645]
- IOC - Artigos de Periódicos [12967]
Metadata
Show full item record
ATAZANAVIR, ALONE OR IN COMBINATION WITH RITONAVIR, INHIBITS SARS-COV-2 REPLICATION AND PROINFLAMMATORY CYTOKINE PRODUCTION
SARS-CoV-2
Antiviral
Atazanavir
Coronavírus
Rede Genômica Fiocruz
GENOMAHCOV
https://www.arca.fiocruz.br/handle/icict/42599
Author
Affilliation
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is already responsible for far more deaths than previous pathogenic coronaviruses (CoVs) from 2002 and 2012. The identification of clinically approved drugs to be repurposed to combat 2019 CoV disease (COVID-19) would allow the rapid implementation of potentially life-saving procedures. The major protease (Mpro) of SARS-CoV-2 is considered a promising target, based on previous results from related CoVs with lopinavir (LPV), an HIV protease inhibitor. However, limited evidence exists for other clinically approved antiretroviral protease inhibitors. Extensive use of atazanavir (ATV) as antiretroviral and previous evidence suggesting its bioavailability within the respiratory tract prompted us to study this molecule against SARS-CoV-2. Our results show that ATV docks in the active site of SARS-CoV-2 Mpro with greater strength than LPV, blocking Mpro activity. We confirmed that ATV inhibits SARS-CoV-2 replication, alone or in combination with ritonavir (RTV) in Vero cells and a human pulmonary epithelial cell line. ATV/RTV also impaired virus-induced enhancement of interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) levels. Together, our data strongly suggest that ATV and ATV/RTV should be considered among the candidate repurposed drugs undergoing clinical trials in the fight against COVID-19.
Keywords in Portuguese
COVID-19SARS-CoV-2
Antiviral
Atazanavir
Coronavírus
Rede Genômica Fiocruz
GENOMAHCOV
Share